What does an antibiotic cost to develop? What is it worth? How to afford it?

Dear All (long, wonkish note alert!):

Today we have a 3-part discussion of cost and value with this summary 3-part message: Developing antibiotics is expensive, Not having antibiotics is even more expensive, and We have to solve this!

First, what does it cost to bring a new antibiotic to market? To start us off, we have this paper that just appeared in JAMA (link): Wouters OJ, McKee M, Luyten J. Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018. JAMA. 2020;323(9):844-53.

In brief, Wouters et al. analyzed public data on R&D spend for new drugs (including biologics) approved by FDA between 2009 and 2018. They were able to obtain complete data on 63 of 355 agents approved during that time and report that the median and mean capitalized R&D cost to bring a drug to market were $985m and $1336m, respectively. For the 5 new antibiotics included in this analysis (eravacycline, oritavancin, fidaxomicin, omadacycline, and ceftolozane-tazobactam), the median and mean costs were $1260m and $1297m.

And, that’s just to get to approval! As we discussed at the 3 Sep 2019 ASM-ESCMID Bootcamp on post-approval economics (link to a newsletter providing an annotated tour of these presentations), you then need something in the range of another $250-$500m over the first 5 years on market to (i) address post-approval commitments and (ii) maintain a supply chain.

Putting it all together, the ~$1.3b to get to approval plus the ~$0.4b post-approval ($1.7b in total) is the break-even cost for the program from Phase 1 to 5 years post-approval (and I’m glossing over issues of time value of money). And, let me emphasize that this cost doesn’t include any additional studies: further work to generate data in other high medical need indications (e.g., nosocomial pneumonia) would be yet additional cost.

If you now look at typical sales for recently approved antibiotics (link to a newsletter analyzing Alan Carr’s Jan 2020 market review), average annual sales are < $50m. There is simply no way to dig out of a $1.7b hole with revenue of $50m/year. The availability of non-dilutive public funding (e.g., push funding from CARB-X, BARDA, Novo REPAIR, etc.) could help shrink the hole, but the math is still challenging.

Second, what’s an antibiotic worth? How much should we plan to pay? We’ve had a variety of conversations on this point and let me point you to a very recent one that was sparked by a paper in CID by Rome & Kesselheim. Here are the papers you need. Papers 1-3 are the recent debate; 4-8 are relevant background papers:

  1. (link) Rome BN, Kesselheim AS. Transferrable Market Exclusivity Extensions to Promote Antibiotic Development: An Economic Analysis. Clin Infect Dis. 2019.
  2. (link) Boucher HW, File TM, Fowler VG, Jezek A, Rex JH, Outterson K. Antibiotic Development Incentives That Reflect Societal Value of Antibiotics. Clinical Infectious Diseases. 2020.
  3. (link) Rome BN, Kesselheim AS. Reply to Boucher, et al. Clinical Infectious Diseases. 2020.
  4. (link) Sertkaya A, Eyraud J, Birkenbach A, Franz C, Ackerley N, Overton V, et al. Analytical framework for examining the value of antibacterial products. Report to US DHHS. United States Department of Health and Human Services. 2014.
  5. (link) Rothery C, Woods B, Schmitt L, Claxton K, Palmer S, Sculpher M. Framework for Value Assessment of New Antimicrobials. 2018.
  6. (link) Outterson K, Rex JH. Evaluating for-profit public benefit corporations as an additional structure for antibiotic development and commercialization. Translational Research. 2020.
  7. (link) Outterson K, McDonnell A. Funding Antibiotic Innovation With Vouchers: Recommendations On How To Strengthen A Flawed Incentive Policy. Health Aff (Millwood). 2016;35(5):784-90.
  8. (link) Outterson K, Samora JB, Keller-Cuda K. Will longer antimicrobial patents improve global public health? Lancet Infect Dis. 2007;7(8):559-66.

Kicking off this second part of our conversation, paper #1 analyzes the cost of paying for new antibiotics using the idea of transferable exclusivity vouchers (TEV) that is suggested by the Re-Valuing Antimicrobial Products (REVAMP) Act introduced in US House of Representatives in 2018. As brief context in case you’ve not run into this idea, a TEV is the idea that the inventor of a new antibiotic receives the right to extend the sales exclusivity period for another drug that does have sales … simplistically, you could think of the second drug as suddenly having a longer patent life.

Rome & Kesselheim analyzed the impact of TEVs would have had on the 10 drugs approved during 2007-2016 that either did (or would have) been eligible for the QIDP (Qualified Infectious Diseases Product) designation that has often been used a standard measure of an interesting new antibiotic. Assuming the TEV was applied to produce maximal value from a second drug that was close to generic entry, the incremental cost to public/private payers of this extended exclusivity would have been $4.5b, a cost that the authors argue may be too expensive.

Responding to that (paper #2), Boucher et al. (and note that I am part of the et al.), use data from paper #4 (Sertkaya et al.) to estimate the societal value of having these antibiotics. Societal values have been discussed in various ways with the work in the UK by Rothery et al. (paper #5) being the most comprehensive summary to date. Societal values could be thought of as the fire extinguisher value of the antibiotic and Rothery identifies 5 such attributes: Spectrum, Transmission, Enablement, Diversity, and Insurance (and in paper #6, Kevin Outterson and I note that you can convert this to the acronym STEDI). And finally, papers #7 and #8 discuss ways that some of the deficiencies of TEVs could be managed.

So, and back to paper #2, Boucher et al. argue that the $4.5b in incremental cost from the TEV would have yielded $29b in societal value, a 644% return. In response, Rome & Kesselheim (paper #3) point out flaws in the value argument, most notably that half of the approved antibiotics were for initially skin infections, an area where we are currently well served with adequate drugs. That’s true, but you have to start somewhere, and it takes time to explore the full potential of any given drug.

To pull it all together, these are substantial values but also substantial sums. If you accept that notion that at least some of the new antibiotics are worth buying on a fire extinguisher basis, we come to the question of how might we pay for even a few new fire extinguishers? On this topic, we come at last to this paper and its accompanying editorial:

  • (link) Årdal C, Lacotte Y, and Ploy M-C, on behalf of the European Union Joint Action on Antimicrobial Resistance Healthcare-Associated Infections (EU-JAMRAI). Financing pull mechanisms for antibiotic-related innovation: Opportunities for Europe. Clinical Infectious Diseases. 2020.
  • (link) Shlaes DM. Can Europe Pull It Together? Clinical Infectious Diseases. 2020.

If you’ve worked your way through all the material on R&D cost and then on antibiotic value, you’ll find that Årdal et al. offers a very helpful recapitulation and summary of those debates in its introduction. The authors then survey such options as DRG (Diagnosis-Related Group) carve-outs, TEVs, stewardship taxes, and a “pay or play” tax on the pharmaceutical industry. Each of the approaches has strengths and weaknesses and the authors note that the models are being reviewed at length in a EU-JAMRAI project (link).

Whew … lots to consider! As I said at the top, the summary is the 3-part message: Developing antibiotics is expensive, Not having antibiotics is even more expensive, and We have to solve this!

And that’s enough for today!

All best wishes, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Operating Partner, Advent Life Sciences. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: https://amr.solutions/blog/. All opinions are my own.

Current funding opportunities:

  • Open now through 16 Mar 2020: CC4CARB, NIAID’s call for applications to fund an innovative Chemistry Center for Combating Antibiotic-Resistant Bacteria (CC4CARB). Go here for details.
  • Open now through 9 Apr 2020: NIAID Broad Agency Announcement (BAA) soliciting contract proposals for preclinical and clinical development of vaccines, therapeutic, and diagnostics for microbial pathogens. Go here for more.
  • Dates for the 2020 funding rounds for Novo REPAIR Impact Fund will be announced May 2020. Go here for current details.
  • 2020 funding rounds for CARB-X have not been announced.

Upcoming meetings of interest to the AMR community:

  • 16-17 Mar 2020 (London): BSAC Spring Conference entitled: “Bridging the gap between science, policy and effective antimicrobial use.” Go here for details. 
  • 20 Mar 2020 (Boston, MA): 7th annual BAARN (Boston Area Antimicrobial Resistance Network) Meeting. Chaired by Lawson Ung and Michael Gilmore, talks start at 9 am and end with a reception at the Harvard Museum of Natural History. Go here to register; you can also contact Lawson Ung (lawson_ung@meei.harvard.edu) for other inquiries.
  • 26 Mar 2020 (online, 17:00-18:30 CET): GARDP REVIVE webinar. Title: “Probability of target attainment analyses for dose selection in antimicrobial drug development,” Speaker: Shampa Das. Go here to register.
  • 26-30 Mar 2020 (Atlanta, GA): CDC- and SHEA-sponsored 6th International Conference on Healthcare Associated Infections. Go here for details.
  • 30 Mar 2020 (everywhere): Deadline for applications for the Molecular Mycology pathogenesis course at Marine Biological Laboratory, Woods Hole. Now in its 24th year, the hands-on residential course runs 17 July to 2 Aug and gets rave reviews. Go here for more.
  • 9 Apr 2020 (everywhere): Final date for applications for NIAID/DMID call (link) for AMR-related vaccines, therapeutics, and diagnostics.
  • 17 Apr 2020 (Paris): Pre-ECCMID workshop entitled “Machine Learning for Clinical Microbiology”. Go here for details. 
  • 18-21 Apr 2020 (Paris): Annual ECCMID meeting (#30)
  • 28 Apr 2020 (online, 17:00-18:30 CEST): GARDP REVIVE webinar. Title: “Inhaled antimicrobials: Do we get the drug to the bug?” Speaker: Harm A. W. M. Tiddens. Go here to register.
  • 5 May 2020 (online, 09:00-10:30 CEST): GARDP REVIVE webinar. Title: “The challenges and opportunities for antimicrobial R&D in low- and middle-income countries – India case study.” Speaker: Anand Anandkumar. Go here to register.
  • 8 May 2020 (Silver Spring): FDA workshop entitled “Developing Antifungal Drugs for the Treatment of Coccidiodomycosis (Valley Fever) Infection.” Go here to register.
  • 25-30 May 2020 (Rotterdam), Annual ESPID meeting (European Society for Pediatric ID, #38)
  • 18-22 Jun 2020 (Chicago), ASM Microbe 2020. Go here for details.
  • 27-28 Jun 2020 (Bryant University, Rhode Island): Drug Resistance Gordon Research Seminar entitled “Mechanisms and Approaches to Overcoming Drug Resistance in Cancer, Infectious Disease and Agriculture” for graduate students and postdoctoral scientists. Go here for details … this immediately precedes the GRC listed just next
  • 28 Jun-3 Jul 2020 (Bryant University, Rhode Island): Gordon Research Conference (GRC) entitled “Strategies to Disrupt Drug Resistance in Infectious Disease, Cancer and Agriculture.” Go here for details.
  • [NEW] 17 Jul-2 Aug 2020 (Marine Biology Laboratory, Woods Hole, MA): Residential course entitled “Molecular Mycology: Current Approaches to Fungal Pathogenesis.” This 2-week intensive training program has run annually for many years and gets outstanding reviews. Go here for details.
  • 2-7 Aug 2020 (Il Ciocco, Tuscany, Italy): Gordon Research Conference (GRC) on Antibacterial Discovery and Development: “Now is the time to re-boot antibiotic R&D before it’s too little, too late.” Go here for details.
  • 24-25 Aug 2020 (Basel): BEAM-, Novo REPAIR-, CARB-X-, DZIF-, ND4BB-, ENABLE-supported (among a long list!) Conference on Novel Antimicrobials and AMR Diagnostics. Details are here.
  • September 2020. University of Sheffield (UK). Applications are being taken for a new 1-year (full-time) or 2-year (part-time) Masters of Science course in Antimicrobial Resistance. The program runs annually from September and covers microbiology, clinical practice and policy. The course webpage is here.
  • 1-4 Sep 2020 (Dublin): Annual ASM-ESCMID Conference on Antibiotic Development #5! Mark your calendar now and go here for details.
  • 9-10 Sep 2020 (Washington, DC): US PACCARB public meeting. Go here for details.
  • 22-25 Sep 2020 (Albuquerque, New Mexico): Biannual meeting of the MSGERC (Mycoses Study Group Education and Research Consortium). Save-the-date announcement is here, details to follow.
  • [REGISTRATION OPENS SOON] 17-25 Oct 2020 (Annecy, France): Interdisciplinary Course on Antibiotics and Resistance (ICARe). This is a soup-to-nuts residential course on antibiotics, antibiotic resistance, and antibiotic R&D. The course is very intense, very detailed, and gets rave reviews. The date is set for 2020 and the program will ultimately appear here. Registration is limited to 40 students and opens 15 Mar 2020.
  • 10-13 Apr 2021 (Vienna): Annual ECCMID meeting (#31)
  • 3-7 Jun 2021 (Anaheim), ASM Microbe 2021. Go here for details.

Share

Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on whatsapp
Share on reddit

In Praise of Non-Inferiority

Dear All (wonkish but intended for everybody to read and absorb): There’s been a lot of recent discussion about “lessons learned from COVID-19.” Indeed, there are many valuable points: global cooperation, preparedness, supply chains, and so forth. As an example, I note the 17 Sep 2020 communique from the G20 Health Ministers (link): it was heavily

FDA and EMA regulatory updates / Fireside chat during the 4th AMR Conference

Dear All (lots and lots of wonkish detail here, be sure your blood caffeine level is adequate!), During the 24-28 Aug 2020 BEAM Alliance-sponsored AMR Conference (go here or see below my signature for more), I had the opportunity on 27 August to chat with Sumati Nambiar (FDA) and Marco Cavaleri (EMA) about ongoing regulatory activities. The

Treating resistant Gram-negatives: IDSA provides pragmatic expert advice

Dear All, IDSA (Infectious Diseases Society of America) have today released an eagerly awaited new guidance document on treating infections due to resistant Gram-negative bacteria (link). The thing that makes this document unusual is that it is an expert guidance rather than a formal guideline. Although there is value in formal guidelines that carefully review

New antibiotics are not being registered or sold in Europe in a timely manner

Dear All (and with thanks to Kevin for leading the charge on this newsletter), While listening to last week’s BEAM-sponsored AMR Conference (really a wonderful conference, thank you Team BEAM, go here to listen to the sessions), we tumbled onto a really, really disturbing trend: New antibiotics are not being registered or sold in Europe in

Scroll to Top